Loading...
01/10 16:39
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects a mixed sentiment. Positive factors include significant revenue growth and reduced operating expenses, but concerns arise from high cash burn and regulatory uncertainties. The Q&A revealed management's optimism about future milestones and automation, yet lacked clarity on certain operational details. Overall, the financial performance and optimistic guidance balance out the risks and uncertainties, leading to a neutral stock price prediction.
Revenue $1.2 million, a growth of 59% over the full year 2023.
Nu.Q Vet Cancer Test Revenue $0.8 million, grew by 75% over the prior year.
Nu.Q Discover Revenue $0.4 million, with year-on-year growth of 40%.
Operating Expenses 23% lower compared to the full year 2023, with second-half operating expenses down 31%.
Net Cash Used in Operating Activities $25.9 million in 2024, compared with $18.1 million in 2023, which benefited from $13 million in milestone payments from Heska.
Cash and Cash Equivalents Approximately $3.3 million at the end of the year.
Non-Dilutive Funding Received approximately $1.8 million in non-dilutive funding payments from agencies in Belgium.
Nu.Q Vet Cancer Test: Expanded access to the Nu.Q Vet Cancer Test across more than 20 countries, sold approximately 120,000 tests in 2024, resulting in a 75% increase in vet revenue compared to 2023.
Nu.Q Discover: Generated approximately $400,000 in revenue in 2024, with over 2,600 samples processed for 13 customers, including 6 pharmaceutical companies.
Nu.Q NETs: Recorded first revenue for Nu.Q NET, marking a significant milestone.
Market Expansion: Nu.Q Vet Cancer Test is now available in over 20 countries, with significant market penetration achieved in Canada, Australia, New Zealand, the U.K., and Japan.
Licensing Agreements: Strong interest in potential out-licensing and/or supply agreements for Nu.Q NETs and oncology portfolio, with ongoing discussions with multiple large companies.
Revenue Growth: Total revenue increased by 59% year-on-year to $1.2 million, with Nu.Q Vet revenue growing by 75%.
Cost Reduction: Operating expenses were reduced by 23% compared to 2023, with second-half expenses down 31%.
Strategic Focus: Aim to sign multiple licensing deals in human diagnostics in 2025, leveraging insights from veterinary licensing negotiations.
Clinical Applications: Nu.Q platform is being positioned for use in regular clinical settings for oncology and NETosis, with CE Marked Nu.Q NETs test purchased by 3 centers of excellence in Europe.
Regulatory Issues: The company faces uncertainties related to regulatory approvals for its Nu.Q platform in human diagnostics, which could impact the timeline for commercialization.
Competitive Pressures: VolitionRx is operating in a highly competitive market for diagnostic screening and liquid biopsy, which may affect its ability to secure licensing deals and market share.
Supply Chain Challenges: The company has identified the need to automate its testing processes to scale operations, indicating potential supply chain challenges in meeting increasing demand.
Economic Factors: The company noted that revenues remain 'lumpy and difficult to predict,' which could be influenced by broader economic conditions affecting healthcare spending.
Funding Risks: While the company has received non-dilutive funding, reliance on such funding sources poses a risk if future grants or financial support are not secured.
Operational Costs: Despite reducing operating expenses, the company reported a significant cash burn of $25.9 million in 2024, raising concerns about financial sustainability.
Licensing Deals: In 2025, VolitionRx aims to sign multiple licensing deals in humans, with strong interest from large companies for both Nu.Q NETs and oncology portfolio.
Revenue Growth: VolitionRx recorded $1.2 million in revenue for 2024, a growth of 59% over 2023, with Nu.Q Vet Cancer Test revenue at $0.8 million, growing by 75%.
Cost Management: Operating expenses were reduced by 23% in 2024 compared to 2023, with a 31% reduction in the second half of 2024.
Cash Neutrality: One of the key financial goals for 2025 is to achieve cash neutrality, meaning income matches expenditure on a cash basis.
Market Expansion: The Nu.Q Vet Cancer Test is now available in over 20 countries, with significant market penetration and ongoing supply agreements.
Clinical Validation: A final validation study for Nu.Q Cancer is underway in Taiwan, with potential inclusion in the national screening program if successful.
Revenue Guidance: VolitionRx will not provide revenue guidance for 2025 at this point due to the unpredictable nature of early-stage commercialization.
Future Revenue Expectations: The company anticipates significant revenue generation from the first human clinical study utilizing Nu.Q Discover biomarkers.
Financial Projections: Cash and cash equivalents at the end of 2024 totaled approximately $3.3 million, with ongoing discussions for additional funding.
Milestone Payments: VolitionRx has received milestone payments of $23 million from previous agreements, contributing to ongoing revenue streams.
Milestone Payments: Received milestone payments of $23 million in addition to ongoing revenue from every test sold.
Cash and Cash Equivalents: Cash and cash equivalents at the end of the year totaled approximately $3.3 million.
Revenue Growth: Revenue was up 59% year-on-year, with Nu.Q Vet Cancer Test revenue growing by 75%.
Operating Expenses: Operating expenses were down 23% on a full-year basis.
Non-Dilutive Funding: Received approximately $1.8 million in non-dilutive funding payments from agencies in Belgium.
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
The earnings call presents mixed signals. While there are positive aspects like revenue growth, cost management, and milestone payments, the absence of revenue guidance and declining cash position raise concerns. The Q&A section reveals uncertainty in revenue predictability and challenges in maintaining cost levels. Overall, the lack of specific guidance and potential financial risks balance out the positives, suggesting a neutral sentiment towards the stock price movement.
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
